Importance of blood pressure lowering in type 2 diabetes: Focus on ADVANCE

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 4, 2010, Pages 340-347

  Chalmers, John ^a   Arima, Hisatomi ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Blood pressure lowering; Indapamide; Perindopril; Type 2 diabetes

Indexed keywords

DIAMICRON MR; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT;

ALBUMINURIA; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG RELEASE; HEART DEATH; HUMAN; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIHYPERTENSIVE AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77951762673     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181d26469     Document Type: Conference Paper

References (30)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes. Estimates for 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
2. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28:2130-2135.
3. Adler A, Stratton I, Neil A, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-419. (Pubitemid 30609443)
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
5. Hansson L, Zanchetti A, Carruthers S, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762. (Pubitemid 28269185)
6. ADVANCE Management Committee. ADVANCE: Action in Diabetes and Vascular Disease-preterax and diamicron MR controlled evaluation. Study rationale and design. Diabetologia. 2001;44:1118-1120.
7. ADVANCE Collaborative Group. Rationale and design of the ADVANCE study: A randomised trial of blood pressure lowering and intensive glucose control in high risk individuals with type 2 diabetes mellitus. J Hypertens. 2001;19:S21-S28.
8. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370:829-840.
9. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560-2572.
10. de Galan BE, Perkovic V, Ninomiya T, et al, on behalf of the ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20:883-892.
11. Ninomiya T, Zounger S, Neal B, et al, for the ADVANCE Collaborative Group. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from ADVANCE trial. J Hypertens. In press.
12. Ninomiya T, Perkovic V, de Galan BE, et al, on behalf of the ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20:1813-1821.
13. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39: S1-S266.
14. Ninomiya T, Zoungas S, de Galan B, et al. The fixed combination of perindopril and indapamide has a great effect on cardiovascular outcomes in patients with type 2 diabetes and albuminuria (Abstract). J Hypertens. 2009;27:S179.
15. Lambers Heerspink HJ, Ninomiya T, Zoungas S, et al. The benefits of a fixed combination of perindopril and indapamide on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (Abstract). Hypertension. In press.
16. de Galan BE, Zoungas S, Chalmers J, et al, for the ADVANCE Collaborative group. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2009;52: 2328-2336.
17. Zoungas S, Ninomiya T, Patel A, et al. The effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes mellitus according to baseline cardiovascular risk in the ADVANCE trial (Abstract). J Hypertens. 2009;27:S314.
18. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25: 1105-1187. (Pubitemid 46924065)
19. Zoungas S, de Galan BE, Ninomiya T, et al, on behalf of the ADVANCE Collaborative Group. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care. 2009;32:2068-2074.
20. Berthold HK, Gouni-Berthold I, Bestehorn KP, et al. Physician gender is associated with the quality of type 2 diabetes care. J Intern Med. 2008; 264:340-350.
21. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and allcause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116:151-157.
22. Andel M, Grzeszczak W, Michalek J, et al, and the DEPAC Group. A multinational, multi-centre, observational, cross-sectional survey assessing diabetes secondary care in Central and Eastern Europe (DEPAC Survey). Diabet Med. 2008;25:1195-1203.
23. Hillier TA, Fosse S, Balkau B, et al. Weight, the metabolic syndrome, and coronary heart disease in type 2 diabetes: Associations among a national French sample of adults with diabetes-the ENTRED study. J Cardiometab Syndr. 2006;1:318-325.
24. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358: 580-591.
25. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet. 2000;355:253-258.
26. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342: 145-153.
27. Lewis E, Hunsicker L, Clarke W, et al, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345: 851-860.
28. Brenner B, Cooper M, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
29. The Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet. 2008;372: 1174-1183.
30. Yusuf S, Diener HC, Sacco RL, et al, for the PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225-1237.